{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:31:36Z","timestamp":1788535896995,"version":"build-2803163510"},"reference-count":44,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Pediatric Hispanic and Black patients with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) experience worse overall survival (OS). We hypothesized that differential outcomes by race and ethnicity following relapse may contribute to disparities. We examined 2053 patients with ALL enrolled in frontline Children\u2019s Oncology Group trials from 1996 to 2014 who relapsed. We assessed the association of race and ethnicity, disease characteristics, and socioeconomic status with relapse survival predictors and postrelapse OS. For noninfant B-ALL, postrelapse OS (P = .002) and disease-related prognosticators such as time to relapse (P = .0002) differed by race and ethnicity. After adjusting for disease and patient characteristics, the OS association with overall race and ethnicity was attenuated, and lost statistical significance; Hispanic ethnicity specifically remained associated with worse OS (hazard ratio [HR], 1.19; 95% confidence interval [CI], 1.01-1.41). Patients from highest annual median household income ZIP codes (&amp;gt;$85\u2009000, approximately the highest quartile of patients) had better 5-year OS than those from the lowest (&amp;lt;$50\u2009000; HR, 0.79; 95% CI, 0.63-0.99). Non-Hispanic Black and Hispanic patients more commonly lived in lower-income ZIP codes. For T-cell ALL, race, ethnicity, and socioeconomic status were not associated with OS. Worse postrelapse outcomes among racial and ethnic minority patients are largely driven by the prevalence of adverse disease-related factors at time of relapse, with a persistent disparity observed in Hispanic patients. The greatest impact in decreasing racial and ethnic B-ALL outcome disparities may be achieved by targeting frontline treatment interventions to address increased relapse among Black and Hispanic patients, and by developing and enabling equitable access to effective relapse treatments such as novel immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016670","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T20:07:08Z","timestamp":1755288428000},"page":"5738-5751","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Role of race and ethnicity in survival among children\/young adults with relapsed ALL: a Children\u2019s Oncology Group report"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-1233","authenticated-orcid":false,"given":"John A.","family":"Ligon","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, University of Florida, Gainesville, FL"},{"name":"2University of Florida Health Cancer Center, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2500-1993","authenticated-orcid":false,"given":"Lingyun","family":"Ji","sequence":"additional","affiliation":[{"name":"3Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Dang","sequence":"additional","affiliation":[{"name":"4Children\u2019s Oncology Group, Monrovia, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Xu","sequence":"additional","affiliation":[{"name":"4Children\u2019s Oncology Group, Monrovia, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-6767","authenticated-orcid":false,"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics and the Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Bhojwani","sequence":"additional","affiliation":[{"name":"6Division of Pediatric Hematology-Oncology, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-3478","authenticated-orcid":false,"given":"Meenakshi","family":"Devidas","sequence":"additional","affiliation":[{"name":"7Department of Global Pediatric Medicine, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kairalla","sequence":"additional","affiliation":[{"name":"2University of Florida Health Cancer Center, Gainesville, FL"},{"name":"8Department of Biostatistics, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Shago","sequence":"additional","affiliation":[{"name":"9Department of Laboratory Medicine and Pathobiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyla A.","family":"Heerema","sequence":"additional","affiliation":[{"name":"10Department of Pathology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Carroll","sequence":"additional","affiliation":[{"name":"11Department of Genetics, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borowitz","sequence":"additional","affiliation":[{"name":"12Department of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7414-3969","authenticated-orcid":false,"given":"Brent L.","family":"Wood","sequence":"additional","affiliation":[{"name":"13Department of Pathology and Laboratory Medicine, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6636-3870","authenticated-orcid":false,"given":"Naomi J.","family":"Winick","sequence":"additional","affiliation":[{"name":"14Department of Pediatrics, University of Texas Southwestern Medical Center, Children\u2019s Health, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Carroll","sequence":"additional","affiliation":[{"name":"15Department of Pediatrics, Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-3957","authenticated-orcid":false,"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics and the Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Raetz","sequence":"additional","affiliation":[{"name":"15Department of Pediatrics, Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-4700","authenticated-orcid":false,"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[{"name":"16Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children\u2019s Research Institute and the Department of Pediatrics, Seattle Children\u2019s Hospital, Fred Hutch Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-3670","authenticated-orcid":false,"given":"Sumit","family":"Gupta","sequence":"additional","affiliation":[{"name":"17Institute of Health Policy, Management and Evaluation, and Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"18Division of Haematology\/Oncology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-1594","authenticated-orcid":false,"given":"Lena E.","family":"Winestone","sequence":"additional","affiliation":[{"name":"19Division of Allergy, Immunology and BMT, Department of Pediatrics, University of California San Francisco Benioff Children\u2019s Hospital, San Francisco, CA"},{"name":"20University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"6","key":"2025112508562529000_bib1","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2002-02-0395","article-title":"Racial and ethnic differences in survival of children with acute lymphoblastic leukemia","volume":"100","author":"Bhatia","year":"2002","journal-title":"Blood"},{"issue":"14","key":"2025112508562529000_bib2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025112508562529000_bib3","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S2352-3026(22)00371-4","article-title":"Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet Haematol"},{"issue":"32","key":"2025112508562529000_bib4","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.19.00812","article-title":"Survival by race and ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: a Children's Oncology Group study","volume":"37","author":"Kahn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025112508562529000_bib5","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"2025112508562529000_bib6","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"2025112508562529000_bib7","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.18.00884","article-title":"Hematopoietic stem-cell transplantation does not improve the poor outcome of children with hypodiploid acute lymphoblastic leukemia: a report from Children's Oncology Group","volume":"37","author":"McNeer","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025112508562529000_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2010-12-322909","article-title":"Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"118","author":"Matloub","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2025112508562529000_bib9","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2010-06-292615","article-title":"Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404)","volume":"118","author":"Asselin","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2025112508562529000_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pbc.25322","article-title":"Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3)","volume":"62","author":"Dreyer","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2025112508562529000_bib11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41375-019-0642-2","article-title":"Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group studies P9904 and P9905","volume":"34","author":"Winick","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2025112508562529000_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/pbc.22944","article-title":"Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906","volume":"57","author":"Bowman","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"2025112508562529000_bib13","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025112508562529000_bib14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.19.01086","article-title":"Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of Children's Oncology Group trial AALL0331","volume":"38","author":"Maloney","year":"2020","journal-title":"J Clin Oncol"},{"issue":"28","key":"2025112508562529000_bib15","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025112508562529000_bib16","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41375-021-01177-6","article-title":"FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631","volume":"35","author":"Brown","year":"2021","journal-title":"Leukemia"},{"issue":"34","key":"2025112508562529000_bib17","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025112508562529000_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MPH.0000000000000589","article-title":"A pilot study of intensified PEG-asparaginase in high-risk acute lymphoblastic leukemia: Children's Oncology Group study AALL08P1","volume":"38","author":"Rodriguez","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"issue":"24","key":"2025112508562529000_bib19","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group study [corrected]","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025112508562529000_bib20","doi-asserted-by":"crossref","first-page":"e29256","DOI":"10.1002\/pbc.29256","article-title":"Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: a report from the Children's Oncology Group study AALL02P2","volume":"68","author":"Hastings","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2025112508562529000_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3324\/haematol.2019.237230","article-title":"Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433","volume":"106","author":"Lew","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"2025112508562529000_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"issue":"25","key":"2025112508562529000_bib23","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025112508562529000_bib24","author":"Kalbfleisch","year":"2002","edition":"2nd ed"},{"key":"2025112508562529000_bib25","volume-title":"Applied Regression Analysis and Other Multivariable Methods","author":"Kleinbaum","year":"2013","edition":"5th ed"},{"key":"2025112508562529000_bib26","volume-title":"Stata Statistical Software: Release 18","year":"2023"},{"issue":"6","key":"2025112508562529000_bib27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/pbc.25928","article-title":"Impact of socioeconomic status on timing of relapse and overall survival for children treated on Dana-Farber Cancer Institute ALL Consortium protocols (2000-2010)","volume":"63","author":"Bona","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2025112508562529000_bib28","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1016\/j.clml.2022.01.001","article-title":"Impact of insurance on overall survival in acute lymphoblastic leukemia: a SEER database study","volume":"22","author":"Joshi","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2025112508562529000_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JOP.2015.005686","article-title":"ReCAP: gaps in insurance coverage for pediatric patients with acute lymphoblastic leukemia","volume":"12","author":"Smits-Seemann","year":"2016","journal-title":"J Oncol Pract"},{"issue":"5","key":"2025112508562529000_bib30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2025112508562529000_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/jamaoncol.2021.6826","article-title":"Association of genetic ancestry with the molecular subtypes and prognosis of childhood acute lymphoblastic leukemia","volume":"8","author":"Lee","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"2025112508562529000_bib32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","article-title":"Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET project","volume":"121","author":"Loh","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2025112508562529000_bib33","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2015.66.3567","article-title":"Racial\/ethnic differences in adverse outcomes among childhood cancer survivors: the childhood cancer survivor study","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025112508562529000_bib34","first-page":"221","article-title":"Poverty and relapse risk in children with acute lymphoblastic leukemia: a Children's Oncology Group study AALL03N1 report","volume":"142","author":"Wadhwa","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025112508562529000_bib35","doi-asserted-by":"crossref","first-page":"e30496","DOI":"10.1002\/pbc.30496","article-title":"Disparities in household material hardship, financial toxicity, and income loss in pediatric cancer","volume":"70","author":"Evans","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2025112508562529000_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.2020006252","article-title":"Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis","volume":"137","author":"Bona","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2025112508562529000_bib37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"2025112508562529000_bib38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/1468-0009.12390","article-title":"Meanings and misunderstandings: a social determinants of health lexicon for health care systems","volume":"97","author":"Alderwick","year":"2019","journal-title":"Milbank Q"},{"issue":"suppl 6","key":"2025112508562529000_bib39","doi-asserted-by":"crossref","first-page":"e30592","DOI":"10.1002\/pbc.30592","article-title":"Children's Oncology Group's 2023 blueprint for research: diversity and health disparities","volume":"70","author":"Winestone","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2025112508562529000_bib40","first-page":"311.e1","article-title":"The choice of either conventional chemotherapy or inotuzumab ozogamicin as bridging regimen does not appear to impact clinical response to CD19-directed CAR-T therapy in pediatric B-ALL","volume":"29","author":"Rubinstein","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"9","key":"2025112508562529000_bib41","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025112508562529000_bib43","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","article-title":"The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes","volume":"6","author":"Faruqi","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2025112508562529000_bib44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.2022017866","article-title":"Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy","volume":"141","author":"Newman","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025112508562529000_bib45","first-page":"356.e1","article-title":"Access to chimeric antigen receptor T cell clinical trials in underrepresented populations: a multicenter cohort study of pediatric and young adult acute lymphoblastic leukemia patients","volume":"29","author":"Hall","year":"2023","journal-title":"Transpl Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5738\/2420147\/blooda_adv-2025-016670-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5738\/2420147\/blooda_adv-2025-016670-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:56:38Z","timestamp":1764078998000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/22\/5738\/546740\/Role-of-race-and-ethnicity-in-survival-among"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":44,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016670","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,25]]},"published":{"date-parts":[[2025,11,13]]}}}